The global disopyramide phosphate market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to boost the market during the forecast period include an increase in the prevalence of arrhythmias and ventricular tachycardia among patients with heart problems, rise in R&D activities to develop advanced products, and significant rise in the geriatric population. However, side effects associated with drugs and stringent government regulations towards the approval of disopyramide phosphate drugs restrict the market growth. An increase in clinical trials and development of drugs with better efficacy and lesser side effects are expected to provide a number of opportunities for pharmaceutical industries, thereby fuelling the growth of the market during the forecast period.

Disopyramide is an antiarrhythmic medication used in the treatment of ventricular tachycardia. It is a sodium channel blocker and therefore classified as a Class 1a anti-arrhythmic agent. Disopyramide has a negative inotropic effect on the ventricular myocardium, significantly decreasing the contractility. Disopyramide also has an anticholinergic effect on the heart which accounts for many adverse side effects. Disopyramide is available in both oral and intravenous forms, and has a low degree of toxicity. Disopyramide phosphate is a class I anti-arrhythmic drug used to treat cardiac arrhythmias. It interferes with the depolarization of the cardiac membrane that results in depressant action on the heart rhythm. The drug is used to treat arrhythmias and prevent paroxysmal supraventricular tachycardia. Disopyramide, despite its efficacy, has one main side effect that has limited its use in the US, though it has seen wider application in Canada, UK and Japan, which is a factor that will propel the market during the forecast period. The global disopyramide phosphate market is segmented on the basis of brand, patient type, and region. Based on drug brand, it is divided into Norpace and Rythmodan. According to patient type, it is segmented into infants, children, adolescents, and geriatric. Geographically, the market is segmented into North America, Europe, Asia-Pacific, and Latin America and Middle-East and Africa.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Drug Brand

o By Patient Type

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: Sanofi S.A., Merck KGaA, and Pfizer Inc., among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Disopyramide Phosphate Market Report by Segment

By Drug Brand

    • Norpace

    • Rythmodan

By Patient Type

    • Infants

    • Children

    • Adolescents

    • Geriatric

Global Disopyramide Phosphate Market Report by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa